Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice

Pharmacological Research

Volumn 58, Issue 1, 2008, Pages 45-51

  Park, Tae Sik ^a   Rosebury, Wendy ^b   Kindt, Erick K ^b   Kowala, Mark C ^b   Panek, Robert L ^b  

^a Gachon University College of Medicine   (South Korea)

^b PFIZER INC   (United States)

Author keywords

Atherosclerosis; Ceramide; Cholesterol; Regression; Sphingomyelin

Indexed keywords

APOLIPOPROTEIN E; CERAMIDE; CHOLESTEROL; COLLAGEN; ENZYME INHIBITOR; PHOSPHATIDYLCHOLINE; SERINE PALMITOYLTRANSFERASE; SPHINGANINE; SPHINGOLIPID; SPHINGOMYELIN; THERMOZYMOCIDIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; AORTA ROOT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRACHIOCEPHALIC TRUNK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; HYPERLIPIDEMIA; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHOLESTEROL; DISEASE PROGRESSION; FATTY ACIDS, MONOUNSATURATED; HYPERLIPIDEMIAS; MALE; MICE; MICE, KNOCKOUT; SERINE C-PALMITOYLTRANSFERASE; SPHINGOLIPIDS; TRIGLYCERIDES;

EID: 50649104363     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.06.005     Document Type: Article

References (36)

1. Summers S.A., and Nelson D.H. A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. Diabetes 54 (2005) 591-602
2. Williams K.J., and Tabas I. Lipoprotein retention and clues for atheroma regression. Arterioscler Thromb Vasc Biol 25 (2005) 1536-1540
3. Williams K.J., and Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15 (1995) 551-561
4. Jeong T., Schissel S.L., Tabas I., Pownall H.J., Tall A.R., and Jiang X. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 101 (1998) 905-912
5. Schissel S.L., Tweedie-Hardman J., Rapp J.H., Graham G., Williams K.J., and Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 98 (1996) 1455-1464
6. Jiang X.C., Paultre F., Pearson T.A., Reed R.G., Francis C.K., Lin M., et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 20 (2000) 2614-2618
7. Schlitt A., Blankenberg S., Yan D., von Gizycki H., Buerke M., Werdan K., et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) 3 (2006) 5
8. Hanada K., Hara T., Nishijima M., Kuge O., Dickson R.C., and Nagiec M.M. A mammalian homolog of the yeast LCB1 encodes a component of serine palmitoyltransferase, the enzyme catalyzing the first step in sphingolipid synthesis. J Biol Chem 272 (1997) 32108-32114
9. Weiss B., and Stoffel W. Human and murine serine-palmitoyl-CoA transferase-cloning, expression and characterization of the key enzyme in sphingolipid synthesis. Eur J Biochem 249 (1997) 239-247
10. Lightle S., Tosheva R., Lee A., Queen-Baker J., Boyanovsky B., Shedlofsky S., et al. Elevation of ceramide in serum lipoproteins during acute phase response in humans and mice: role of serine-palmitoyl transferase. Arch Biochem Biophys 419 (2003) 120-128
11. Fujita T., Inoue K., Yamamoto S., Ikumoto T., Sasaki S., Toyama R., et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) 47 (1994) 208-215
12. Park T.S., Panek R.L., Mueller S.B., Hanselman J.C., Rosebury W.S., Robertson A.W., et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 110 (2004) 3465-3471
13. Park T.S., Panek R.L., Rekhter M.D., Mueller S.B., Rosebury W.S., Robertson A., et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 189 (2006) 264-272
14. Worgall T.S., Juliano R.A., Seo T., and Deckelbaum R.J. Ceramide synthesis correlates with the posttranscriptional regulation of the sterol-regulatory element-binding protein. Arterioscler Thromb Vasc Biol 24 (2004) 943-948
15. Kieft K.A., Bocan T.M., and Krause B.R. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography. J Lipid Res 32 (1991) 859-866
16. Folch J., Lees M., and Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226 (1957) 497-509
17. Homan R., and Anderson M.K. Rapid separation and quantitation of combined neutral and polar lipid classes by high-performance liquid chromatography and evaporative light-scattering mass detection. J Chromatogr B: Biomed Sci Appl 708 (1998) 21-26
18. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97 (1998) 2433-2444
19. Hojjati M.R., Li Z., Zhou H., Tang S., Huan C., Ooi E., et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 280 (2005) 10284-10289
20. Glaros E.N., Kim W.S., Wu B.J., Suarna C., Quinn C.M., Rye K.A., et al. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol 73 (2007) 1340-1346
21. Garner B., Priestman D.A., Stocker R., Harvey D.J., Butters T.D., and Platt F.M. Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. J Lipid Res 43 (2002) 205-214
22. Ichi I., Nakahara K., Miyashita Y., Hidaka A., Kutsukake S., Inoue K., et al. Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids 41 (2006) 859-863
23. Hanada K. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim Biophys Acta 1632 (2003) 16-30
24. Bismuth J., Lin P., Yao Q., and Chen C. Ceramide: a common pathway for atherosclerosis?. Atherosclerosis (2007)
25. Worgall T.S. Sphingolipids: major regulators of lipid metabolism. Curr Opin Clin Nutr Metab Care 10 (2007) 149-155
26. Kim W.S., Chalfant C.E., and Garner B. Fine tuning therapeutic targeting of the sphingolipid biosynthetic pathway to treat atherosclerosis. Curr Vasc Pharmacol 4 (2006) 151-154
27. Glaros E.N., Kim W.S., Quinn C.M., Jessup W., Rye K.A., and Garner B. Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. J Lipid Res 49 (2008) 324-331
28. Glaros E.N., Kim W.S., Rye K.A., Shayman J.A., and Garner B. Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein-E null mice. J Lipid Res (2008)
29. Aikawa M., Rabkin E., Voglic S.J., Shing H., Nagai R., Schoen F.J., et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res 83 (1998) 1015-1026
30. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
31. Neve B.P., Fruchart J.C., and Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 60 (2000) 1245-1250
32. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., and Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (2000) 523-531
33. Collins A.R., Meehan W.P., Kintscher U., Jackson S., Wakino S., Noh G., et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 365-371
34. Bea F., Blessing E., Bennett B.J., Kuo C.C., Campbell L.A., Kreuzer J., et al. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 60 (2003) 198-204
35. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
36. Holland W.L., Brozinick J.T., Wang L.P., Hawkins E.D., Sargent K.M., Liu Y., et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5 (2007) 167-179